Literature DB >> 7850787

Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26.

M Toyoshima1, M Nakajima, T Yamori, T Tsuruo.   

Abstract

A platelet-aggregating sialoglycoprotein with a molecular weight of 44,000 (gp44) was immunochemically purified from highly metastatic mouse adenocarcinoma cells. The rat monoclonal antibody (mAb) 8F11 used in the purification procedure has been generated previously against NL-17 cells derived from the mouse colon 26 cell line, mAb 8F11 inhibits NL-17 cells from inducing platelet aggregation and suppresses their experimental metastasis to the lung. The purified gp44 induced mouse platelet aggregation in a dose-dependent manner without any plasma component. This aggregation was completely inhibited by mAb 8F11. The gp44 was partially characterized by sequential enzymatic hydrolysis of carbohydrates and was found to be O-glycans enriched. When gp44 was sequentially treated with N-glycanase and neuraminidase, it lost platelet aggregation activity. Further treatment with O-glycanase resulted in a loss of the reactivity to mAb 8F11. These results suggest that sialylated carbohydrate chains of gp44 are involved in the induction of platelet aggregation and may play an important role in the colonization of NL-17 cells in the lung.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium.

Authors:  Y J Kim; L Borsig; H L Han; N M Varki; A Varki
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma.

Authors:  Tohru Ikeda; Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Yuu Ozaki-Honda; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

3.  Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Authors:  Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina; Tohru Ikeda
Journal:  Pathol Oncol Res       Date:  2013-11-28       Impact factor: 3.201

4.  P-selectin deficiency attenuates tumor growth and metastasis.

Authors:  Y J Kim; L Borsig; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 5.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

6.  Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity.

Authors:  A Plotnikov; D Fishman; T Tichler; R Korenstein; Y Keisari
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

7.  Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.

Authors:  Takaya Sekiguchi; Ai Takemoto; Satoshi Takagi; Kazuki Takatori; Shigeo Sato; Miho Takami; Naoya Fujita
Journal:  Oncotarget       Date:  2016-01-26

Review 8.  Platelet aggregation in the formation of tumor metastasis.

Authors:  Takashi Tsuruo; Naoya Fujita
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2008       Impact factor: 3.493

Review 9.  Platelet-activating factor podoplanin: from discovery to drug development.

Authors:  Ai Takemoto; Kenichi Miyata; Naoya Fujita
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

10.  A Real-Time Near-Infrared Fluorescence Imaging Method for the Detection of Oral Cancers in Mice Using an Indocyanine Green-Labeled Podoplanin Antibody.

Authors:  Akihiro Ito; Mitsuhiko Ohta; Yukinari Kato; Shunko Inada; Toshio Kato; Susumu Nakata; Yasushi Yatabe; Mitsuo Goto; Norio Kaneda; Kenichi Kurita; Hayao Nakanishi; Kenji Yoshida
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.